Trial Profile
Therapy-optimizing pilot study to investigate the efficacy and safety of an induction therapy with Campath-1H in combination with Tacrolimus for prevention of acute and chronic rejection in patients after primary orthotopic heart transplantation
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Aug 2011
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Tacrolimus (Primary) ; Immunosuppressants
- Indications Heart transplant rejection
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 12 Aug 2011 New trial record